ScinoPharm Taiwan Ltd 2016 SR
The report highlights ScinoPharm Taiwan's sustainability performance for 2016, marking its 20th anniversary. Key achievements include an 11% growth in operating margin and being ranked in the top 5% of public companies in the TWSE corporate governance evaluation for two consecutive years. The company generated 36,516 kWh of solar power and maintained a strong focus on anti-cancer API development, holding 753 drug master files worldwide. It also emphasized employee well-being, receiving recognition as a unit of excellence for promoting a healthy workplace.
Company: ScinoPharm Taiwan Ltd
Sector: Manufacturing
Country: Taiwan
Year: 2016
Type: SR
Pages: 44
Back to company
ScinoPharm Taiwan Ltd
Corporate Social Responsibility Report
The report highlights ScinoPharm Taiwan's sustainability performance for 2016, marking its 20th anniversary. Key achievements include an 11% growth in operating margin and being ranked in the top 5% of public companies in the TWSE corporate governance evaluation for two consecutive years. The company generated 36,516 kWh of solar power and maintained a strong focus on anti-cancer API development, holding 753 drug master files worldwide. It also emphasized employee well-being, receiving recognition as a unit of excellence for promoting a healthy workplace.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Jan 1, 2016 - Dec 31, 2016
Fiscal Year
2016
Published
Jul 14, 2017
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Women on Board
Women in Management
Workplace Fatalities
Employees